

Gabriella Pellegriti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/527490/publications.pdf>

Version: 2024-02-01

63
papers

5,825
citations

159358

30
h-index

118652

62
g-index

69
all docs

69
docs citations

69
times ranked

5286
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer. <i>Thyroid</i> , 2021, 31, 224-232.	2.4	30
2	Heavy Metals in the Environment and Thyroid Cancer. <i>Cancers</i> , 2021, 13, 4052.	1.7	24
3	Concentration of Metals and Trace Elements in the Normal Human and Rat Thyroid: Comparison with Muscle and Adipose Tissue and Volcanic Versus Control Areas. <i>Thyroid</i> , 2020, 30, 290-299.	2.4	11
4	The new AJCC/TNM Staging System (VIII ed.) in papillary thyroid cancer: clinical and molecular impact on overall and recurrence free survival. <i>Annals of Translational Medicine</i> , 2020, 8, 838-838.	0.7	4
5	Increased Thyroid Cancer Incidence in Volcanic Areas: A Role of Increased Heavy Metals in the Environment?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3425.	1.8	20
6	Giant parathyroid adenoma: a rare cause of primary hyperparathyroidism mimicking a carcinoma. <i>Endokrynologia Polska</i> , 2020, 71, 359-360.	0.3	3
7	Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. <i>European Journal of Cancer</i> , 2019, 118, 35-40.	1.3	70
8	EP-1773 Radioiodine therapy: a dosimetric study in a patient with DTC after rhTSH stimulation. <i>Radiotherapy and Oncology</i> , 2019, 133, S958.	0.3	0
9	Thyroidectomy as Treatment of Choice for Differentiated Thyroid Cancer. <i>International Journal of Surgical Oncology</i> , 2019, 2019, 1-7.	0.3	5
10	Absorbed Dose Evaluation in Radioiodine Therapy with Different Approaches. <i>Instruments</i> , 2019, 3, 39.	0.8	1
11	Response to Letter to the Editor: "Time to Separate Persistent From Recurrent Differentiated Thyroid Cancer: Different Conditions With Different Outcomes". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5110-5111.	1.8	2
12	Time to Separate Persistent From Recurrent Differentiated Thyroid Cancer: Different Conditions With Different Outcomes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 258-265.	1.8	48
13	Effect of low-dose tungsten on human thyroid stem/precursor cells and their progeny. <i>Endocrine-Related Cancer</i> , 2019, 26, 713-725.	1.6	10
14	Lymph node location is a risk factor for papillary thyroid cancer-related death. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 1349-1353.	1.8	19
15	Differentiated thyroid cancer in children: Heterogeneity of predictive risk factors. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27226.	0.8	10
16	Editorial: Clinical and Molecular Epidemiology of Thyroid Cancer of Follicular Origin. <i>Frontiers in Endocrinology</i> , 2018, 9, 67.	1.5	7
17	Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 849-876.	1.8	165
18	Prognostic factors in adrenocortical carcinoma: data from a large Polish series. <i>Polish Archives of Internal Medicine</i> , 2018, 128, 330-332.	0.3	0

#	ARTICLE	IF	CITATIONS
19	Tall cell and diffuse sclerosing variants of papillary thyroid cancer: outcome and predicting value of risk stratification methods. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 1235-1241.	1.8	19
20	Latero-cervical lymph node metastases (N1b) represent an additional risk factor for papillary thyroid cancer outcome. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 1355-1363.	1.8	37
21	Anaplastic Thyroid Cancer in Sicily: The Role of Environmental Characteristics. <i>Frontiers in Endocrinology</i> , 2017, 8, 277.	1.5	9
22	Thyroid Cancer in the Pediatric Age in Sicily: Influence of the Volcanic Environment. <i>Anticancer Research</i> , 2017, 37, 1515-1522.	0.5	17
23	Prognostic Factors for Adrenocortical Carcinoma Outcomes. <i>Frontiers in Endocrinology</i> , 2016, 7, 99.	1.5	33
24	Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidism. <i>Clinical Endocrinology</i> , 2016, 84, 614-619.	1.2	26
25	Reply to the Letter to the Editor by Sollini M et al.. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 487-488.	1.8	2
26	A novel RET gene mutation in a patient with apparently sporadic pheochromocytoma. <i>Endocrine Journal</i> , 2016, 63, 87-91.	0.7	1
27	Outcome of the Diffuse Sclerosing Variant of Papillary Thyroid Cancer: A Meta-Analysis. <i>Thyroid</i> , 2016, 26, 1285-1292.	2.4	40
28	Association of autoimmune thyroid diseases, chronic atrophic gastritis and gastric carcinoid: experience from a single institution. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 779-784.	1.8	25
29	Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 341-347.	1.8	30
30	Metastatic malignant struma ovarii with coexistence of Hashimoto's thyroiditis. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2016, 2016, 160030.	0.2	1
31	Familial Non-Medullary Thyroid Cancer Represents an Independent Risk Factor for Increased Cancer Aggressiveness: A Retrospective Analysis of 74 Families. <i>Frontiers in Endocrinology</i> , 2015, 6, 117.	1.5	35
32	Several Site-specific Cancers are Increased in the Volcanic Area in Sicily. <i>Anticancer Research</i> , 2015, 35, 3995-4001.	0.5	13
33	Cardiac Arrest After Intravenous Calcium Administration for Calcitonin Stimulation Test. <i>Thyroid</i> , 2014, 24, 606-607.	2.4	17
34	The influence of the environment on the development of thyroid tumors: a new appraisal. <i>Endocrine-Related Cancer</i> , 2014, 21, T235-T254.	1.6	46
35	The <i>BRAF</i> ^{V600E} Mutation Influences the Short- and Medium-Term Outcomes of Classic Papillary Thyroid Cancer, But Is Not an Independent Predictor of Unfavorable Outcome. <i>Thyroid</i> , 2014, 24, 1267-1274.	2.4	30
36	Increased Mortality in Patients With Differentiated Thyroid Cancer Associated With Graves' Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1014-1021.	1.8	66

#	ARTICLE	IF	CITATIONS
37	Thyroid Cancer in Thyroglossal Duct Cysts Requires a Specific Approach due to Its Unpredictable Extension. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 458-465.	1.8	46
38	Papillary Thyroid Microcarcinomas: A Comparative Study of the Characteristics and Risk Factors at Presentation in Two Cancer Registries. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1427-1434.	1.8	80
39	Descriptive Epidemiology of Human Thyroid Cancer: Experience From a Regional Registry and The "Volcanic Factor". <i>Frontiers in Endocrinology</i> , 2013, 4, 65.	1.5	39
40	Worldwide Increasing Incidence of Thyroid Cancer: Update on Epidemiology and Risk Factors. <i>Journal of Cancer Epidemiology</i> , 2013, 2013, 1-10.	0.5	936
41	The tall cell variant of papillary thyroid carcinoma: clinical and pathological features and outcomes. <i>Journal of Endocrinological Investigation</i> , 2013, 36, 249-54.	1.8	22
42	Update on thyroid cancer treatment. <i>Future Oncology</i> , 2012, 8, 1331-1348.	1.1	33
43	Risk-Adapted Management of Differentiated Thyroid Cancer Assessed by a Sensitive Measurement of Basal Serum Thyroglobulin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1703-1709.	1.8	108
44	Levothyroxine Monotherapy Cannot Guarantee Euthyroidism in All Athyreotic Patients. <i>PLoS ONE</i> , 2011, 6, e22552.	1.1	234
45	Response: Re: Papillary Thyroid Cancer Incidence in the Volcanic Area of Sicily. <i>Journal of the National Cancer Institute</i> , 2010, 102, 915-916.	3.0	2
46	Papillary Thyroid Cancer Incidence in the Volcanic Area of Sicily. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1575-1583.	3.0	138
47	BRAF(V600E) mutation and the biology of papillary thyroid cancer. <i>Endocrine-Related Cancer</i> , 2008, 15, 191-205.	1.6	210
48	Consenso europeo para el tratamiento de los pacientes con carcinoma tiroideo diferenciado del epitelio folicular. <i>Endocrinología Y Nutrición: Organo De La Sociedad Espanola De Endocrinología Y Nutrición</i> , 2007, 54, 390.e1-390.e16.	0.8	0
49	European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. <i>European Journal of Endocrinology</i> , 2006, 154, 787-803.	1.9	1,804
50	Clinical Behavior and Outcome of Papillary Thyroid Cancers Smaller than 1.5 cm in Diameter: Study of 299 Cases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 3713-3720.	1.8	299
51	The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels. <i>Clinical Endocrinology</i> , 2003, 58, 556-561.	1.2	30
52	Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. <i>British Journal of Cancer</i> , 2003, 88, 1537-1542.	2.9	129
53	Differentiated thyroid cancer in children and adolescents. <i>Journal of Endocrinological Investigation</i> , 2002, 25, 18-24.	1.8	73
54	Long-term outcome of patients with insular carcinoma of the thyroid. <i>Cancer</i> , 2002, 95, 2076-2085.	2.0	77

#	ARTICLE	IF	CITATIONS
55	Usefulness of Recombinant Human Thyrotropin in the Radiometabolic Treatment of Selected Patients with Thyroid Cancer. <i>Thyroid</i> , 2001, 11, 1025-1030.	2.4	46
56	Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p?DDD) levels on the treatment of patients with adrenocortical carcinoma. <i>Cancer</i> , 2001, 92, 1385-1392.	2.0	222
57	Immunostaining for Met/HGF Receptor May be Useful to Identify Malignancies in Thyroid Lesions Classified Suspicious at Fine-Needle Aspiration Biopsy. <i>Thyroid</i> , 2001, 11, 783-787.	2.4	23
58	Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. <i>British Journal of Cancer</i> , 2000, 83, 715-718.	2.9	119
59	Gastroenteropancreatic neuroendocrine tumor metastases to the thyroid gland: differential diagnosis with medullary thyroid carcinoma. <i>European Journal of Endocrinology</i> , 1999, 140, 187-191.	1.9	39
60	Outcome of Differentiated Thyroid Cancer in Gravesâ€™™ Patients1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2805-2809.	1.8	115
61	Outcome of Differentiated Thyroid Cancer in Graves' Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2805-2809.	1.8	98
62	False positive 131I total body scan due to bilateral polycystic renal disease. <i>Journal of Endocrinological Investigation</i> , 1997, 20, 342-344.	1.8	15
63	Early occurrence of a thyroid carcinoma in a patient who developed Gravesâ€™™ disease after treatment for Hodgkinâ€™™s disease. <i>Journal of Endocrinological Investigation</i> , 1995, 18, 869-871.	1.8	4